BAYRY
Bayer Aktiengesellschaft
OTC Markets OTCQXUSDEQUITY
Healthcare
DELAYED
Neutral
-2/100
Last price
12.42
▲ 0.03 (0.24%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
12.39
Day high
12.61
Day low
12.40
Volume
151.26K
Market cap
$48.81B
P/E (TTM)
—
52W range
7.48 – 15.23
Trailing performance
Returnvs SPY
1W
-10.58%
-12.5%
1M
-12.47%
-13.6%
3M
-14.05%
-18.6%
6M
+8.47%
-9.7%
YTD
+14.79%
+0.5%
1Y
+47.51%
+31.1%
3Y
+3.50%
-78.8%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on BAYRY open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
0
Total on file
Fundamentals
Market cap$48.81B
Enterprise value$82.28B
Revenue (TTM)$45.38B
Gross profit$27.43B
EBITDA$10.13B
Net income$-1.74B
EPS (TTM)$-0.51
Free cash flow$6.56B
Total cash$5.08B
Total debt$38.43B
Book value / share$8.44
Shares outstanding3.93B
Float3.93B
Short % of float—
Dividend yield0.26%
Beta (5Y)0.84
Valuation & profitability ratios
Trailing P/E—
Forward P/E9.05
PEG ratio4.61
Price / sales—
Price / book1.47
EV / revenue1.81
EV / EBITDA8.12
Gross margin60.46%
Operating margin9.19%
Profit margin-3.83%
Return on equity-5.69%
Return on assets3.18%
Debt / equity129.36
Current ratio1.04
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $45.58B | $46.61B | $47.64B | $50.74B | -2.2% |
| Operating revenue | $45.58B | $46.61B | $47.64B | $50.74B | -2.2% |
| Cost of revenue | $18.80B | $21.27B | $19.75B | $19.87B | -11.6% |
| Gross profit | $26.78B | $25.34B | $27.89B | $30.87B | +5.7% |
| Research & development | $5.77B | $6.21B | $5.37B | $6.57B | -7.1% |
| Selling, general & admin | $14.71B | $15.94B | $14.94B | $16.92B | -7.7% |
| Total operating expense | $20.64B | $22.01B | $19.85B | $23.54B | -6.2% |
| Operating income | $6.14B | $3.33B | $8.04B | $7.33B | +84.5% |
| Net interest income | -$1.86B | -$1.90B | -$1.61B | -$1.82B | +2.1% |
| Pre-tax income | -$3.13B | -$2.33B | -$1.62B | $4.67B | -34.1% |
| Tax provision | $466.00M | $212.00M | $1.32B | $504.00M | +119.8% |
| Net income | -$3.62B | -$2.55B | -$2.94B | $4.15B | -41.8% |
| Net income to common | -$3.62B | -$2.55B | -$2.94B | $4.15B | -41.8% |
| Basic EPS | -0.92 | -0.65 | -0.75 | 1.06 | -41.5% |
| Diluted EPS | -0.92 | -0.65 | -0.75 | 1.06 | -41.5% |
| EBIT | -$864.00M | $24.00M | $426.00M | $6.53B | -3,700.0% |
| EBITDA | $1.92B | $8.81B | $10.45B | $13.03B | -78.2% |
| Basic shares | 3.93B | 3.93B | 3.93B | 3.93B | 0.0% |
| Diluted shares | 3.93B | 3.93B | 3.93B | 3.93B | 0.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $6.67B | $6.19B | $5.91B | $5.17B | +7.8% |
| Cash & short-term investments | $7.86B | $8.09B | $10.59B | $10.15B | -2.9% |
| Accounts receivable | $9.08B | $8.97B | $9.34B | $10.31B | +1.2% |
| Inventory | $12.34B | $13.40B | $13.93B | $13.60B | -8.0% |
| Total current assets | $32.91B | $34.44B | $37.56B | $37.76B | -4.5% |
| Property, plant & equipment | $12.65B | $13.46B | $13.32B | $13.67B | -6.0% |
| Goodwill & intangibles | $48.68B | $52.13B | $55.66B | $63.83B | -6.6% |
| Total assets | $104.54B | $110.85B | $116.26B | $124.88B | -5.7% |
| Total current liabilities | $32.59B | $28.95B | $29.46B | $35.08B | +12.5% |
| Current debt | $4.39B | $4.90B | $4.41B | $7.26B | -10.4% |
| Long-term debt | $30.78B | $34.55B | $37.23B | $32.83B | -10.9% |
| Total debt | $36.45B | $40.70B | $42.87B | $41.32B | -10.4% |
| Total liabilities | $78.48B | $78.81B | $83.18B | $85.95B | -0.4% |
| Shareholder equity | $25.95B | $31.91B | $32.93B | $38.77B | -18.7% |
| Working capital | $326.00M | $5.49B | $8.10B | $2.68B | -94.1% |
| Net tangible assets | -$22.74B | -$20.22B | -$22.73B | -$25.06B | -12.4% |
| Shares issued | 982.42M | 982.42M | 982.42M | 982.42M | 0.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$3.60B | -$2.55B | -$2.94B | $4.17B | -41.2% |
| Depreciation & amortisation | $2.79B | $8.78B | $10.02B | $6.50B | -68.3% |
| Change in working capital | $5.93B | $85.00M | -$4.07B | -$2.70B | +6,881.2% |
| Operating cash flow | $5.93B | $7.37B | $5.12B | $7.09B | -19.5% |
| Capital expenditure | -$2.49B | -$2.78B | -$2.75B | -$2.95B | +10.5% |
| Investing cash flow | -$1.27B | $164.00M | -$3.52B | -$2.38B | -874.4% |
| Share buybacks | -$14.00M | -$16.00M | -$24.00M | -$25.00M | +12.5% |
| Dividends paid | -$127.00M | -$131.00M | -$2.38B | -$1.99B | +3.1% |
| Financing cash flow | -$3.88B | -$7.18B | -$679.00M | -$4.22B | +45.9% |
| Free cash flow | $3.44B | $4.59B | $2.37B | $4.14B | -25.0% |
| End cash position | $6.67B | $6.19B | $5.91B | $5.17B | +7.8% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $10.87B | $13.40B | $11.44B | $9.66B | $10.74B | — | -18.9% |
| Operating revenue | $10.87B | $13.40B | $11.44B | $9.66B | $10.74B | — | -18.9% |
| Cost of revenue | $4.54B | $5.23B | $4.50B | $4.31B | $4.36B | — | -13.2% |
| Gross profit | $6.33B | $8.17B | $6.94B | $5.35B | $6.38B | — | -22.5% |
| Research & development | $1.52B | $1.42B | $1.41B | $1.50B | $1.41B | — | +7.0% |
| Selling, general & admin | $3.96B | $3.70B | $4.05B | $3.40B | $3.54B | — | +7.2% |
| Total operating expense | $5.50B | $4.64B | $2.59B | $5.90B | $6.36B | — | +18.5% |
| Operating income | $827.00M | $3.53B | $4.34B | -$543.00M | $13.00M | — | -76.6% |
| Net interest income | -$424.00M | -$516.00M | -$319.00M | -$632.00M | -$401.00M | — | +17.8% |
| Pre-tax income | $321.00M | $2.99B | -$3.37B | -$1.16B | -$426.00M | — | -89.3% |
| Tax provision | $92.00M | $222.00M | $378.00M | -$202.00M | -$236.00M | — | -58.6% |
| Net income | $219.00M | $2.76B | -$3.76B | -$963.00M | -$199.00M | — | -92.1% |
| Net income to common | $219.00M | $2.76B | -$3.76B | -$963.00M | -$199.00M | — | -92.1% |
| Basic EPS | 0.06 | 0.70 | — | -0.25 | -0.05 | 0.33 | -91.8% |
| Diluted EPS | 0.06 | 0.70 | — | -0.25 | -0.05 | 0.33 | -91.8% |
| EBIT | $755.00M | $3.46B | -$2.95B | -$399.00M | -$36.00M | — | -78.2% |
| EBITDA | $1.91B | $4.72B | -$2.61B | $606.00M | $236.00M | — | -59.4% |
| Basic shares | 3.93B | 3.93B | — | 3.93B | 3.93B | 3.93B | 0.0% |
| Diluted shares | 3.93B | 3.93B | — | 3.93B | 3.93B | 3.93B | 0.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $4.29B | $5.73B | $6.67B | $5.90B | $4.56B | -25.1% |
| Cash & short-term investments | $5.08B | $6.66B | $7.86B | $7.24B | $5.50B | -23.7% |
| Accounts receivable | $12.88B | $12.91B | $9.08B | $9.99B | $12.88B | -0.2% |
| Inventory | $11.97B | $12.01B | $12.34B | $12.33B | $12.11B | -0.4% |
| Total current assets | $33.64B | $35.30B | $32.91B | $32.88B | $33.75B | -4.7% |
| Property, plant & equipment | $12.76B | $12.73B | $12.65B | $12.48B | $12.47B | +0.2% |
| Goodwill & intangibles | $49.36B | $48.85B | $48.68B | $48.05B | $48.31B | +1.0% |
| Total assets | $107.28B | $107.94B | $104.54B | $104.21B | $105.24B | -0.6% |
| Total current liabilities | $32.27B | $33.46B | $32.59B | $28.96B | $29.78B | -3.6% |
| Current debt | — | — | $4.39B | — | — | — |
| Long-term debt | — | — | $30.78B | — | — | — |
| Total debt | — | — | $36.45B | — | — | — |
| Total liabilities | $77.58B | $78.98B | $78.48B | $74.51B | $74.74B | -1.8% |
| Shareholder equity | $29.58B | $28.84B | $25.95B | $29.58B | $30.37B | +2.6% |
| Working capital | $1.37B | $1.84B | $326.00M | $3.92B | $3.97B | -25.4% |
| Net tangible assets | -$19.77B | -$20.01B | -$22.74B | -$18.47B | -$17.94B | +1.2% |
| Shares issued | 982.42M | 982.42M | 982.42M | 982.42M | 982.42M | 0.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | $229.00M | $2.77B | -$3.75B | -$959.00M | -$190.00M | -91.7% |
| Depreciation & amortisation | $1.16B | $1.25B | $334.00M | $1.00B | $272.00M | -7.7% |
| Change in working capital | -$951.00M | -$6.16B | $7.38B | $1.43B | $1.31B | +84.5% |
| Operating cash flow | $690.00M | -$1.79B | $4.20B | $1.69B | $1.06B | +138.5% |
| Capital expenditure | -$660.00M | -$411.00M | -$798.00M | -$836.00M | -$465.00M | -60.6% |
| Investing cash flow | -$707.00M | $280.00M | -$518.00M | -$1.07B | $154.00M | -352.5% |
| Dividends paid | -$112.00M | — | -$11.00M | -$8.00M | -$108.00M | — |
| Financing cash flow | -$1.48B | $528.00M | -$2.89B | $730.00M | -$482.00M | -379.7% |
| Free cash flow | $30.00M | -$2.21B | $3.40B | $849.00M | $593.00M | +101.4% |
| End cash position | $4.29B | $5.73B | $6.67B | $5.90B | $4.56B | -25.1% |
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | 0.25 | 0.27 | +7.2% |
| Mar 2026 | 0.62 | 0.79 | +29.1% |
| Dec 2025 | 0.16 | 0.18 | +13.5% |
| Sep 2025 | 0.13 | 0.17 | +30.9% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | 0.16 | 1 | $9.98B | +3.3% |
| Next quarter | 0.07 | 1 | $11.72B | +2.5% |
| Current year | 1.30 | 2 | $45.90B | +0.7% |
| Next year | 1.37 | 2 | $47.06B | +2.5% |
Analyst targets & ownership
Mean target$15.90
High target$16.68
Low target$15.30
Implied upside27.98%
Analyst count4
ConsensusBUY
Strong buy / Buy2 / 1
Hold1
Sell / Strong sell0 / 0
Held by insiders0.00%
Held by institutions0.34%
Institutions holding23
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
13.46
-7.69% from price
SMA 20
13.77
-9.79% from price
SMA 50
13.96
-11.00% from price
SMA 100
12.99
-4.42% from price
SMA 200
12.39
+0.27% from price
EMA 12
13.30
-6.60% from price
EMA 26
13.65
-9.02% from price
EMA 50
13.65
-9.02% from price
RSI (14)
28.3
Oversold
MACD (12,26,9)
-0.35
Hist -0.21
ATR (14)
0.35
2.83% of price
Realised vol 30D
28.4%
Annualised
Bollinger upper
15.06
20, 2σ
Bollinger lower
12.47
20, 2σ
50 / 200 cross
Golden
13.96 vs 12.39
Trend bias
Above 200
+0.27%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.57
Less volatile than market
Correlation to SPY
0.18
Largely independent
Realised vol 30D
28.4%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-31.4%
Peak to trough
Max drawdown 5Y
-73.7%
Peak to trough
ATR 14
0.35
2.83% of price
Beta (reported)
0.84
5Y monthly, from filing
Short interest
Shares short
0
Prior 611.19K
Change vs prior
-100.0%
Shorts covering
% of float
—
—
% of shares out
0.00%
Against total outstanding
Days to cover
0.0
Liquid
Float
3.93B
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 1, 20 | Citigroup | DOWNGRADE | Buy | Neutral |
| Aug 15, 18 | Jefferies | DOWNGRADE | Buy | Hold |
| Aug 25, 16 | Citigroup | UPGRADE | Neutral | Buy |
| Dec 2, 14 | Morgan Stanley | UPGRADE | Equal-Weight | Overweight |
Dividends & splits
Forward rate$0.03 / yr
Forward yield0.26%
5-year avg yield0.66%
Payout ratio171.29%
Ex-dividend dateApr 28, 2026
Next pay dateMay 11, 2026
Last split4:1
Split dateSep 20, 2017
SEC filings
Headlines
Bayer (XTRA:BAYN) Could Be 24% Undervalued As $2.2b Ohio Drug Hub Takes Shape
Simply Wall St. · 13h ago
Stock Market Today, Oct. 6: Corteva Rallies 12% on Analyst Upgrade Following Spin Off
Motley Fool · 15h ago
Bayer to invest $2.2B in Ohio pharmaceutical facility
Manufacturing Dive · 21h ago
Mint Pharmaceuticals Inc. and Bayer Inc. Expand Distribution Partnership in Canada
CNW Group · 24h ago
Mint Pharmaceuticals Inc. and Bayer Inc. Expand Distribution Partnership in Canada
PR Newswire · 24h ago
Is Baxter International (BAX) Stock Outpacing Its Medical Peers This Year?
Zacks · 1d ago
Optogenetics researchers win a Nobel Prize; Roche bets on Alector brain drug
BioPharma Dive · 2d ago
Bayer plans $2.2bn pharmaceutical manufacturing facility in Ohio, US
Pharmaceutical Technology · 2d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.